文献速递药物相互作用特殊人群用药

利福平联用下阿扎那韦/利托那韦与多替拉韦的细胞内渗透:剂量递增研究

Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study.
PubMed 文献 · Clin Pharmacol Ther · 2025-01-31

阿扎那韦/利托那韦增至300/100 mg每日两次可恢复细胞内浓度至无利福平水平,多替拉韦细胞内浓度随剂量递增显著升高,利福平加倍未见额外影响。

要点

  • 阿扎那韦/利托那韦增至300/100 mg每日两次可补偿利福平所致细胞内暴露下降。
  • 多替拉韦细胞内浓度随阿扎那韦/利托那韦剂量递增显著升高,与血浆变化相似。
  • 进一步加倍利福平剂量未对PBMC内阿扎那韦/利托那韦浓度产生额外影响。

核心结论

  • 增加阿扎那韦/利托那韦剂量可在细胞内水平补偿利福平效应,支持临床使用。

研究设计与样本

  • 试验含四个连续阶段:PK1(阿扎那韦/利托那韦300/100 mg每日一次)、PK2(加用利福平600 mg每日一次和多替拉韦50 mg每日两次,2周)、PK3(阿扎那韦/利托那韦增至300/100 mg每日两次,1周)、PK4(利福平剂量加倍,1周)。
  • 采用LC-MS/MS法测定血浆和PBMC中阿扎那韦、利托那韦和多替拉韦的稳态浓度。

主要发现

  • PK3与PK1相比,阿扎那韦细胞内浓度的几何均值比为0.99(CI90 0.72-1.41)。
  • 多替拉韦细胞内浓度随阿扎那韦/利托那韦剂量递增显著升高,与血浆变化相似。
  • 进一步增加利福平剂量未对PBMC内阿扎那韦/利托那韦浓度产生额外影响。

临床怎么用

  • 对于需联用利福平的HIV感染者,可将阿扎那韦/利托那韦剂量增至300/100 mg每日两次以维持细胞内暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ritonavir-boosted atazanavir is a victim of drug-drug interaction with rifampicin, a key component of antitubercular treatment. In a recent dose escalation clinical trial, we showed that increasing atazanavir/ritonavir to 300/100 mg b.i.d. compensates for reduced drug exposure in plasma due to rifampicin, but the intracellular effects remained unexplored. This sub-study investigated the intracellular penetration of atazanavir/ritonavir and dolutegravir into peripheral blood mononuclear cells (PBMC). Twenty-six healthy volunteers living with HIV, virologically suppressed, and taking atazanavir/ritonavir containing regimens were enrolled. The trial consisted of four sequential periods: PK1, participants were on atazanavir/ritonavir 300/100 mg q.d.; at PK2, rifampicin 600 mg q.d. and dolutegravir 50 mg b.i.d. were added (2 weeks); at PK3, atazanavir/ritonavir dose was increased to 300/100 mg b.i.d. (1 week); at PK4, rifampicin dose was doubled (1 week). Atazanavir, ritonavir, and dolutegravir were quantified in plasma and PBMC using LC-MS/MS methods to evaluate steady-state concentrations at the end of each period. Atazanavir/ritonavir dose escalation successfully restored intracellular concentrations comparable to those observed without rifampicin, with a geometric mean ratio of 0.99 (CI90 0.72-1.41) for atazanavir at PK3 compared with PK1. The intracellular concentration of dolutegravir increased significantly with atazanavir/ritonavir dose escalation, similar to plasma. Finally, further, increasing the rifampicin dose did not show an additional impact on atazanavir/ritonavir concentrations in PBMC. The study confirms that increasing the ATV/r dose can be an effective strategy for compensating rifampicin effects even at the intracellular level, supporting its use in clinical settings.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. De Nicolò A, Palermiti A, Mugerwa H, et al. Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study. Clin Pharmacol Ther. 2025. PMID: 39891354. doi:10.1002/cpt.3572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。